/
ELAN
$24.85+$0.11 (+0.44%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$12.3B
499M shares
52-week range
$13.39 – $27.72
80% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-10.15
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.07B | $3.07B | $3.27B | $4.76B | $4.41B | $4.42B | $4.44B | $4.71B |
| Cost of revenue | $1.77B | $1.67B | $2.03B | $2.69B | $2.44B | $2.48B | $2.53B | $2.67B |
| Gross profit | $1.30B | $1.40B | $1.25B | $2.08B | $1.97B | $1.94B | $1.91B | $2.05B |
| Gross margin | 42.2% | 45.6% | 38.1% | 43.6% | 44.7% | 43.9% | 43.0% | 43.5% |
| R&D | $246.6M | $270.1M | $327.0M | $369.0M | $321.0M | $327.0M | $344.0M | $368.0M |
| Operating income | $313.8M | $370.0M | −$76.8M | $304.0M | $384.0M | $326.0M | $251.0M | $252.0M |
| EBITDA | $439.7M | $471.6M | $900.0K | $409.0M | $866.0M | −$224.0M | $1.49B | $676.0M |
| Net income | $86.5M | $67.9M | −$560.1M | −$483.0M | −$78.0M | −$1.23B | $338.0M | −$232.0M |
| Net margin | 2.8% | 2.2% | -17.1% | -10.1% | -1.8% | -27.9% | 7.6% | -4.9% |
| EPS (diluted) | 0.28 | 0.18 | -1.27 | -0.97 | -0.15 | -2.50 | 0.68 | -0.47 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $5.1B | $1.07 | $0.99–$1.40 | 10 |
| 2027 | $5.3B | $1.19 | $1.03–$1.57 | 10 |
| 2028 | $5.6B | $1.36 | $0.47–$2.49 | 6 |
| 2029 | $5.9B | $1.46 | $1.43–$1.48 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$5.45
Price
$24.85
Implied downside
-78%
Peer comparison
Elanco Animal Health Incorporated Common Stock
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
www.elanco.com- Employees
- 9,900
- IPO / List date
- Sep 20, 2018
- HQ
- INDIANAPOLIS, IN
Held by traders on TradeandTell
No one on the platform currently holds ELAN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2026-03-31 | 86,190 | $2.1M |
| Renaissance Technologiesas of 2025-03-31 | 33,144 | $348.0K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ELAN yet.
